[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]
[In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?]
Rev Med Interne. 2019 Dec 04;:
Authors: Lanthier L, Huard G, Plourde MÉ, Cauchon M
PMID: 31812446 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Internal Medicine | Invokana | SGLT2 Inhibitors